Recent Collaboration Highlights
May 2026 — Inbrija® Licensing-In Collaboration
- Supported strategic business development activities contributing to the successful licensing of Inbrija® for Greater China.
- The collaboration involved scientific evaluation, partner engagement, and cross-border transaction support between international innovators and Chinese pharmaceutical partners.
- Read the Official Collaboration Announcement
May 2025 — Bijuva® Licensing-In Collaboration
- Supported cross-border business development activities contributing to the successful licensing and commercialization of Bijuva® in Greater China. The collaboration involved opportunity identification, scientific evaluation, partner engagement, and transaction support between Theramex and Jincheng Pharmaceutical.
- Read the Official Collaboration Announcement
Selected Ongoing Licensing-Out Programs
| Program | Modality / Area | Development Status | Lead Focus |
|---|---|---|---|
| Drug #1 | Biologic | Clinical-stage | Metabolic / MASH |
| Drug #2 | Monoclonal antibody | Clinical-stage | Immunology / CKD-related anemia |
| Drug #3 | Small molecule | Clinical-stage | Pulmonary fibrosis |
| Drug #4 | Small molecule | Clinical-stage | Autoimmune / CNS |
| Drug #5 | Biologic | Clinical-stage | Immunology |